Supplementary Online Content

Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. *JAMA*. doi:10.1001/jama.2014.15688.

This supplementary material has been provided by the authors to give readers additional information about their work.

© 2014 American Medical Association. All rights reserved.

eTable 1. List of HARMONIZE Sites and Investigators (by Country)

Country Investigator name and affiliation	Number of patients enrolled	Percentage enrolled
United States	206	79.8%
Ravindra Agarwal, Agarwal Nephrology and Hypertension, Columbus, GA		
Rajesh Ailani, PCCC of Volusia, New Smyrna Beach, FL		
Sreedhara Alla, Northwest Louisiana Nephrology, Shreveport, LA		
Sady Alpizar, Clinical Research Trials of Florida, Tampa, FL		
German Alvarez, Clinical Research of Brandon, Brandon, FL		
Saadat Ansari, Saadat Ansari Internal Medicine, Huntsville, AL		
Stella Awua-Larbi, Kidney Care Center, Joliet, IL		
Anthony Bartkowiak, Blair Medical Associates, Altoona, PA		
Kai Sheng Chang, Lakeview Clinical Research, Summerfield, FL		
Louis Chaykin, Meridien Research, Bradenton, FL		
Robert Cohen, Southwest Clinical Research Institute, Tempe, AZ		
Paul Crawford, Research by Design, Evergreen Park, IL		
Sachin Desai, AKDHC MEDICAL RESEARCH SVCS, Phoenix, AZ		
Mohamed El-Shahawy, Academic Medical Research Institute, Los Angeles, CA		
Julio Fernandez-Bombino, San Marcus Research Clinic, Miami, FL		
Almena Free, Pinnacle Research Group, Anniston, AL		
Claude Galphin, Southeast Renal Research Inst., Chattanooga, TN		
David Halpert, JEM research institute, Atlantis, FL		
Susan Hole, Riverside Clinical Research, Edgewater, FL		
Mohammad Ismail, Mohammad Ismail MD, Inc., Paramount, CA		
Younus Ismail, Scottsboro Quick Care Clinic, Scottsboro, AL		
Samuel Kantor, NKDHC Research Dept, Las Vegas, NV		
Mikhail Kosiborod, Saint Lukes Lipid and Diabetes Research Center, Kansas City, MO		
Jorge Kusnir, Florida Pulmonary Research Inst, Winter Park, FL		
Harold Locay, Discovery Medical Research, Ocala, FL		
Kelli Maw, Meridien Research, Brooksville, FL		
Moustafa Moustafa, South Carolina Nephrology & Hypertension, Orangeburg, SC		
Jesus Navarro, Genesis Clinical Research Corp, Tampa, FL		
Wajeh Qunibi, University of Texas Health Science Center at San Antonio, San Antonio, TX		
Javier Ricardo, Empire Clinical Research, Miami Lakes, FL		
John Robertson, Apex Research of Riverside, Riverside, CA		
Mercedes Samson, American Clinical Trials, Hawaiian Gardens, CA		
Luis Serentill, Savin Medical Group, Miami Lakes, FL		
Zeev Sharon, Atlanta Nephrology Referral Center, Decatur, GA		
Douglas Shemin, Rhode Island Hospital, Providence, RI		
Kenneth Smith, Clinical Research Institute of Michigan, Chesterfield, MI		
Bruce Spinowitz, Nephrology Associates, Flushing, NY		
Pusadee Suchinda, Carolina Diabetes and Kidney Center, Sumter, SC		
Jalal Taslimi, Medical Consulting Center, Miami, FL		
Robert Weiss, Maine Research Associates, Auburn, ME		
Theodossis Zacharis, Creekside Clinical Research, Deland, FL		
South Africa	32	12.4%
Graham Ellis, Helderberg Clinical Trials Centre, Somerset West, South Africa		
Zelda Punt, Phoenix Pharma, Port Elizabeth, South Africa		
Tasneem Vally, Synexus Watermeyer Clinical Research Centre, Meyerspark, Pretoria, South Africa		
Australia	20	7.8%
Steve Holt, Royal Melbourne Hospital, Parkville, Australia		
Peter Mount, Austin Hospital, Heidelberg, Australia		
David Mudge, Princess Alexandra Hospital, Woolloongabba, Australia		
David Packham, Melbourne Medical Research Group, Melbourne, Australia		
Simon Roger, Renal Research, Gosford, Australia		
Total	258	100%

© 2014 American Medical Association. All rights reserved.

eTable 2. Summary of treatment-related adverse events occurring in 2 or more patients

System Organ Class Preferred Term	Open-Label Phase	Randomized Phase			
	Zirconium Cyclosilicate 10g (N=258)		Zirconium Cyclosilicate Dose		
		Placebo (n=85)	5g (n=45)	10g (n=51)	15g (n=56)
Any Event	6 (2.3)	7 (8.2)	3 (6.7)	3 (5.9)	6 (10.7)
Blood and Lymphatic System Disorders					
Anemia	0	0	0	0	2 (3.6)
Gastrointestinal Disorders					
Constipation	1 (0.4)	4 (4.7)	0	0	1 (1.8)
Diarrhea	3 (1.2)	0	0	0	0
Dyspepsia	1 (0.4)	0	1 (2.2)	0	0
Investigations					
Electrocardiogram QT prolonged	1 (0.4)	0	0	0	1 (1.8)
Renal and Urinary Disorders					
Dysuria	0	1 (1.2)	1 (2.2)	0	0

© 2014 American Medical Association. All rights reserved.

eFigure. Mean serum potassium across pre-specified subgroups of chronic kidney disease (CKD), heart failure (HF), diabetes mellitus (DM), and concomitant RAASi (renin angiotensin aldosterone system inhibitor) use.



Mean serum potassium across pre-specified subgroups of chronic kidney disease (CKD), heart failure (HF), diabetes mellitus (DM), and concomitant RAASi (renin angiotensin aldosterone system inhibitor) use. Mean serum potassium levels over Days 8-29 of the randomized phase are shown for patients receiving placebo versus once daily zirconium cyclosilicate (A) 5g, (B) 10g, and (C) 15g.

© 2014 American Medical Association. All rights reserved.